Second-generation synthetic glycopeptide platforms such as MUC1-STn constructs linked to T-helper epitopes or formulated on nanoparticle carriers have elicited class-switched IgG and cytolytic T cell responses that recognize glycosylated MUC1 on tumor cells [50,211,212,213,214]. The gene discussed is MUC1; the disease is neoplasm.